Endometrial Cancer Clinical Trials (as of August 12, 2020)

ENGOT-en12/NOGGO/INCYTE

Leading group: NOGGO

Clinical Trial Study: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)

Number of patients accrued: 0

Planned number of patients: 220

Participating groups:

BGOG, GINECO, HECOG, MITO

Planned start in 3Q 2020

 

ENGOT-en11/BGOG/KEYNOTE-B21

Leading group: BGOG

Clinical Trial Study: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without (Chemo)Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Carcinoma After Surgery With Curative Intent

Number of patients accrued: 0

Planned number of patients: 990

Participating groups:

A-AGO, AGO, CEEGOG, GEICO, GINECO, HECOG, ISGO, PGOG, TRSGO, MITO, NCRI, NSGO

Planned start in 4Q 2020

 

ENGOT-en10/BGOG/DUO-E

Leading group: BGOG

Clinical Trial Study: A Phase 3 trial with Durvalumab-Olaparib in newly diagnosed advanced and recurrent endometrial cancer

Number of patients accrued: 6

Planned number of patients: 699

Participating groups:

NOGGO, HECOG, ISGO, PGOG, NSGO, CEEGOG

Planned start in 1Q 2020

 

ENGOT-en9/A-AGO/LEAP-001

Leading group: A-AGO

Clinical Trial Study: A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)

Number of patients accrued: 405

Planned number of patients: 720

Participating groups:

BGOG, GEICO, NOGGO, ISGO, MITO, PGOG, CTI, NCRI, TRSGO

  

ENGOT-en8/GINECO/ROCSAN

Leading group: GINECO

Clinical Trial Study: ROCSAN study: A multicentric randomized phase II/III evaluating TSR-042 (anti-PD-1 mAb) in combination with Niraparib (parpi) versus Niraparib alone compared to chemotherapy in the treatment of metastatic or recurrent endometrial or ovarian carcinosarcoma after at least one line of chemotherapy

Number of patients accrued: 4

Planned number of patients:  63 in phase 1, 170 in phase 2

Participating groups:

AGO, GEICO, MITO

Planned start in 3Q 2019

  

ENGOT-en7/MaNGO/atTEnd

Leading group: MaNGO

Clinical Trial Study: AtTEnd trial: Phase III double-blind randomized placebo controlled trial of Atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer

Number of patients accrued: 237

Planned number of patients: 550

Participating groups:

GEICO, SAKK, A-AGO, AGO, NCRI, JGOG, ANZGOG, TGOG, KGOG

FPI October 2018

 

ENGOT-en6/NSGO/RUBY

Leading group: NSGO

Clinical Trial Study: A phase III, randomized, open-label study of TSR-042, an Anti-PD-1 monoclonal antibody, versus investigator´s choice chemotherapy in patients with advanced/recurrent endometrial cancer

Number of patients accrued: 171

Planned number of patients: 470

Participating groups:

TBA

 

ENGOT-en5/BGOG-en5/SIENDO

Leading group: BGOG

Clinical Trial Study: A randomized phase III trial of maintenance with Selinexor/placebo after combination chemotherapy for patients with advanced or reccurent endometrial cancer

Number of patients accrued: 91

Planned number of patients: 192

Participating groups:

CEEGOG, GEICO, MITO, NOGGO, ISGO